Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor
A technology for bufatalin and gynecological tumors, which is applied to the application field of bufatalin and its salts in the preparation of medicines for treating gynecological tumors, can solve the problems such as the complex composition of toad preparations, and achieves strong anti-gynecological tumor effect. Convenient clinical application, clear effect of active ingredients
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0028] Example 1: Inhibitory effect of bufasterene extract, cinobufafelin, bufafalin, bufafalin or jenobufafalin on human ovarian cancer cell A2780.
[0029] According to the method of MTT experiment, the inhibitory effects of bufadene extract and four monomeric compounds cinobufagin, bufafelin, bufafetolin or jenobufafeline on human ovarian cancer cells (A2780) were investigated.
[0030] The experimental results showed that the bufasterene extract and the four monomeric compounds cinobufagin, bufafelin, bufafetalin or bufafetalin all had a strong inhibitory effect on human ovarian cancer cells (A2780). Each dose group showed a better dose-effect relationship, and bufafetobufalin showed better anti-human ovarian cancer cell (A2780) activity, and its IC50 value of 59.948nM was lower than that of other drug groups. The specific experimental results are shown in Table 1 and Table 2.
[0031] Table 1 The effect of bufasterene extract on human ovarian cancer cells (A2780)
[0032]...
Embodiment 2
[0035] Example 2: Inhibitory effect of bufasterene extract, cinobufagin, bufafelin, bufafetal or jenobufafeline on human ovarian cancer cells (SK-OV-3).
[0036] Inhibitory effects of bufadene extract and four monomeric compounds cinobufagin, bufafelin, bufafetolin or jenobufafeline on human ovarian cancer cells (SK-OV-3) were investigated according to the MTT assay method .
[0037] The experimental results showed that the bufasterene extract and the four monomeric compounds cinobufagin, bufafelin, bufafetolin or jenobufafeline all had a strong effect on human ovarian cancer cells (SK-OV-3). Inhibitory effect, each dose group showed a better dose-effect relationship, among which bufafetobufalin showed better activity against human ovarian cancer cells (SK-OV-3), and its IC50 value was 76.83nM less than that of other drugs Group. The specific experimental results are shown in Table 3 and Table 4.
[0038] Table 3 Effects of bufasterene extract on human ovarian cancer cells ...
Embodiment 3
[0042] Example 3: Inhibitory effect of bufadene extract, cinobufagin, bufafelin, bufafetal or jenobufafeline on human cervical cancer cells (SiHa).
[0043] Inhibitory effects of bufadene extract and four monomeric compounds cinobufagin, bufafelin, bufafetolin or jenobufafeline on human ovarian cancer cells (SK-OV-3) were investigated according to the MTT assay method .
[0044] The experimental results showed that the bufasterene extract and the four monomeric compounds cinobufagin, bufafalin, bufafalin or jenobufafeline all had strong inhibitory effects on human cervical cancer cells (SiHa). Dosage groups showed a better dose-effect relationship, among which bufafetoxin showed better activity against human cervical cancer cells (SiHa), and its IC50 value was 85.001nM which was lower than that of other drug groups. The specific experimental results are shown in Table 5 and Table 6.
[0045] Table 5 Effect of bufasterene extract on human cervical cancer cells (SiHa)
[0046...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com